Bio-Techne Corporation TECH
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Ask Irving AI About TECH
Get to know the stock you’re researching through a simple conversation. Ask Irving about its Weiss rating, financial health, dividends, and potential risks — right from the stock page.
Get answers about this stock. Instantly.
Ask about the company’s financial health and its Weiss Safety, Reward, and Risk Ratings, with answers grounded in Weiss Ratings data.
Understand the numbers behind the rating.
Explore profits, cash flow, valuation, and dividends. Ask follow-up questions without leaving the stock page.
Put the stock’s strengths and risks in context.
Look beyond a single number. Explore rating changes and company trends to better understand the stock’s outlook.
Company Overview
Bio-Techne Corporation (NASDAQ: TECH) is a U.S.-based life sciences and diagnostics company that develops and manufactures biotechnology reagents, analytical instruments, and diagnostic products used in biological research, clinical diagnostics, and cell and gene therapy development. The company operates primarily within the biotechnology tools and diagnostics industries, serving pharmaceutical companies, biotechnology firms, academic institutions, hospitals, and clinical laboratories. Its core revenue drivers include protein analysis products, immunoassays, molecular diagnostics solutions, and cell therapy workflow tools. Bio-Techne is widely recognized for its portfolio of high-quality antibodies, proteins, assays, and genomic analysis technologies used in biomedical research and translational medicine.
The company traces its origins to 1976 and evolved through a combination of organic product development and strategic acquisitions. Bio-Techne expanded significantly through the integration of brands such as R&D Systems, ProteinSimple, ACD, and Exosome Diagnostics, which broadened its capabilities across proteomics, genomics, spatial biology, and precision diagnostics. The company has positioned itself as a supplier of specialized, high-value research and clinical tools with recurring demand characteristics and strong exposure to growth areas such as cell and gene therapy, spatial biology, and molecular diagnostics.
Business Operations
Bio-Techne organizes its operations into two primary reportable segments: Protein Sciences and Diagnostics and Spatial Biology. The Protein Sciences segment generates revenue through the sale of reagents, antibodies, proteins, immunoassays, and analytical instrumentation used in research and bioprocessing applications. This segment includes major brands such as R&D Systems, Novus Biologicals, ProteinSimple, and TOCRIS. The Diagnostics and Spatial Biology segment includes molecular diagnostics products, spatial genomics technologies, and clinical testing services through businesses such as Advanced Cell Diagnostics (ACD) and Exosome Diagnostics. Revenue is generated through direct product sales, instrument placements, consumables, licensing, and service-based laboratory testing.
The company operates across North America, Europe, and Asia-Pacific through direct sales channels and distribution networks. Bio-Techne controls proprietary technologies in protein analysis, capillary electrophoresis, RNA in situ hybridization, and exosome-based diagnostics. Strategic collaborations with pharmaceutical and biotechnology companies support companion diagnostics development and cell therapy manufacturing workflows. The company also maintains manufacturing, R&D, and distribution facilities globally to support product development and customer demand across regulated and research-use markets.
Strategic Position & Investments
Bio-Techne’s strategic direction focuses on expanding its position in high-growth life sciences markets, particularly cell and gene therapy, spatial biology, precision diagnostics, and biopharma analytical tools. The company has invested heavily in automation technologies, advanced proteomic analysis systems, and molecular profiling platforms designed to support translational research and therapeutic development. Acquisitions have played a central role in its growth strategy, including the acquisitions of ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Lunaphore, each of which expanded the company’s capabilities in analytical instrumentation, spatial genomics, liquid biopsy diagnostics, and tissue analysis technologies.
The company has also invested in manufacturing expansion and bioprocessing capabilities to support increasing demand from pharmaceutical and cell therapy customers. Emerging technology exposure includes spatial multiomics, automated tissue imaging, exosome-based liquid biopsy applications, and analytical platforms used in biologics development. Bio-Techne’s portfolio strategy emphasizes recurring consumables revenue tied to installed instrument bases and proprietary reagent ecosystems, helping strengthen long-term customer retention and operating leverage.
Geographic Footprint
Bio-Techne is headquartered in Minneapolis, Minnesota, and maintains a significant global operating footprint across North America, Europe, and Asia-Pacific. The company operates manufacturing, research, and commercial facilities in the United States, the United Kingdom, China, Germany, Switzerland, and other international markets. Its products are sold globally through direct commercial operations and third-party distributors, supporting customers in academic research, pharmaceutical development, and clinical diagnostics.
The company has expanded its international presence through acquisitions and localized commercial infrastructure, particularly in Europe and Asia. International markets represent a meaningful portion of total revenue, with growing exposure to biopharmaceutical research activity in China and broader Asia-Pacific markets. Bio-Techne’s global supply chain and technical support operations are designed to support multinational pharmaceutical customers and research institutions operating across multiple continents.
Leadership & Governance
Bio-Techne’s leadership team combines expertise in life sciences tools, diagnostics, healthcare operations, and biotechnology commercialization. The company’s governance structure reflects a focus on scientific innovation, operational efficiency, disciplined acquisitions, and long-term shareholder value creation. Strategic leadership has emphasized expanding the company’s presence in high-growth research and clinical markets while integrating acquired technologies into scalable commercial platforms.
Key executives include:
- Kim Kelderman – President and Chief Executive Officer
- James Hippel – Chief Financial Officer
- Kimberly Talvitie – Chief Human Resources Officer
- Charles Kummeth – Former President and Chief Executive Officer; current strategic advisor roles referenced in prior filings
- Brian Lantz – Executive Vice President, General Counsel and Corporate Secretary
The company’s leadership philosophy has consistently emphasized scientific quality, customer-driven innovation, and targeted acquisitions to expand technological capabilities and market reach. Public disclosures in SEC filings, earnings materials, and investor presentations indicate continued prioritization of advanced analytical technologies and translational medicine applications as core long-term strategic themes.